Frasier Syndrome
|
0.080 |
Biomarker
|
disease |
BEFREE |
Germline intronic mutations leading to the loss of the +KTS isoforms have been observed in all patients with Frasier syndrome.
|
16927106 |
2006 |
Nephroblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Three types of WT1 messages (total, exon 5(+) and KTS(+)) and WT1 immunostaining of these diseases were analyzed.
|
17803653 |
2007 |
Malignant Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status.
|
17886559 |
2007 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We detected an unusual shift of WT1 isoforms towards WT1(+17AA/+KTS) in melanoma.
|
17912546 |
2008 |
Frasier Syndrome
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Here we show that a decrease in WT1 + KTS isoforms due to disruption of alternative splicing of the WT1 gene in a FS patient is associated with diminished expression of the transcription factors SRY and SOX9 in Sertoli cells.
|
18271004 |
2008 |
Desmoplastic Small Round Cell Tumor
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A defining characteristic of DSRCT is a specific chromosomal translocation, t(11;22)(p13;q12), that fuses EWS with WT1, leading to a production of two isoforms of chimeric transcription factor, EWS/WT1(-KTS) and EWS/WT1(+KTS).
|
18523561 |
2008 |
Gonadoblastoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Frasier syndrome is characterized by a 46 XY disorder of sex development, nephropathy, and increased risk for gonadoblastoma due to Wilms tumor 1(WT1) mutation in the donor splice site of intron-9, resulting in the splice form +KTS.
|
19653292 |
2009 |
Nephroblastoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
(1) KTS mutations cause isolated NS with absence of WT in 46,XX females.
|
20595692 |
2010 |
Frasier Syndrome
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
(2) KTS mutations cause Frasier syndrome with gonadoblastoma risk in 46,XY phenotypic females.
|
20595692 |
2010 |
Childhood Kidney Wilms Tumor
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
(1) KTS mutations cause isolated NS with absence of WT in 46,XX females.
|
20595692 |
2010 |
Gonadoblastoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
(2) KTS mutations cause Frasier syndrome with gonadoblastoma risk in 46,XY phenotypic females.
|
20595692 |
2010 |
Nephrotic Syndrome
|
0.020 |
GeneticVariation
|
group |
BEFREE |
(3) KTS mutations cause NS with a slower progression when compared with missense mutations.
|
20595692 |
2010 |
Chronic kidney disease stage 5
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Patients with KTS mutations presented at a significantly older age and with a slower progression toward chronic kidney disease (CKD) stage 5, compared with missense mutations.
|
20595692 |
2010 |
Chronic Kidney Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Patients with KTS mutations presented at a significantly older age and with a slower progression toward chronic kidney disease (CKD) stage 5, compared with missense mutations.
|
20595692 |
2010 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Alternative splicing at two sites yields four major isoforms, 17AA(+)KTS(+), 17AA(+)KTS(-), 17AA(-)KTS(+), and 17AA(-)KTS(-), and all the isoforms are expressed in the malignancies.
|
25418835 |
2015 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
WT1 has several alternative splicing products, one of which, the KTS(+) variant, has been demonstrated to be involved in the transcriptional activation of a variety of oncogenes as well as the inhibition of tumor suppressor genes.
|
25434383 |
2014 |
Nephrotic Syndrome
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Nine (82 %) patients with missense mutations presented with congenital/infantile nephrotic syndrome, while 8 (80 %) with KTS splicing mutations presented with childhood-onset SRNS.
|
27300205 |
2017 |
Chronic kidney disease stage 5
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Progression to end-stage renal disease (ESRD) was noted in all patients with missense mutations (median age, 2.6 months; interquartile range [IQR], 0.8 months to 1.7 years) and in 5 patients with KTS splicing mutations (median, 9.3 years; IQR, 3.3-16.5 years).
|
27300205 |
2017 |
Kidney Failure, Chronic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Progression to end-stage renal disease (ESRD) was noted in all patients with missense mutations (median age, 2.6 months; interquartile range [IQR], 0.8 months to 1.7 years) and in 5 patients with KTS splicing mutations (median, 9.3 years; IQR, 3.3-16.5 years).
|
27300205 |
2017 |
Steroid-resistant nephrotic syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Nine (82 %) patients with missense mutations presented with congenital/infantile nephrotic syndrome, while 8 (80 %) with KTS splicing mutations presented with childhood-onset SRNS.
|
27300205 |
2017 |
Steroid resistant nephrotic syndrome of childhood
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Nine (82 %) patients with missense mutations presented with congenital/infantile nephrotic syndrome, while 8 (80 %) with KTS splicing mutations presented with childhood-onset SRNS.
|
27300205 |
2017 |
Nephroblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Distinct global binding patterns of the Wilms tumor gene 1 (WT1) -KTS and +KTS isoforms in leukemic cells.
|
27612989 |
2017 |
Childhood Kidney Wilms Tumor
|
0.040 |
Biomarker
|
disease |
BEFREE |
Distinct global binding patterns of the Wilms tumor gene 1 (WT1) -KTS and +KTS isoforms in leukemic cells.
|
27612989 |
2017 |
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our study provides evidence that WT1 -KTS and WT1 +KTS share target genes yet still bind distinct locations, indicating isoform-specific regulation in transcription of genes related to cell proliferation and differentiation, consistent with the involvement of WT1 in acute myeloid leukemia.
|
27612989 |
2017 |
Klippel-Trenaunay-Weber Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Total N<sub>2</sub>O emissions were reduced significantly by all KTS treatments as a function of KTS rate.
|
29128773 |
2018 |